Does vitreomacular traction hinder the effectiveness of anti-VEGF therapy in a patient with exudative age-related macular degeneration?
In this case, the presence of vitreomacular traction seemed to hinder resolution of submacular exudation after intravitreal injection of bevacizumab. The role of the vitreomacular interface in the effectiveness of antivascular endothelial growth factor therapy in exudative AMD should be considered.
We conclude that "clear" or "Hurler" cells are valvular interstitial cells with the immunohistochemical phenotype of activated myofibroblasts and may be engaged, albeit ineffectively, in valve repair.